{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:53:29Z","timestamp":1792518809095,"version":"4.5.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.ijrobp.2025.08.060","type":"journal-article","created":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T22:21:58Z","timestamp":1758579718000},"page":"1318-1328","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Five-Year Survival and Safety of SABR in Patients with Unresectable Locally Advanced Non-Small Cell Lung Cancer unfit for Concurrent Radio-chemotherapy: Focus on Patterns of Local Recurrence from the START-NEW-ERA Non-randomized Phase 2 Trial"],"prefix":"10.1016","volume":"124","author":[{"given":"Fabio","family":"Arcidiacono","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Anselmo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelina","family":"Casale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Zannori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Loreti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetta","family":"Enrico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Tassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro Di","family":"Marzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Italiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo Arruda","family":"Viani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto","family":"Maranzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Trippa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2025.08.060_bib0001","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1200\/JCO.2009.26.2543","article-title":"Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer","volume":"28","author":"Aup\u00e9rin","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.08.060_bib0002","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non\u2013small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2025.08.060_bib0003","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.21.01308","article-title":"Five-year survival outcomes from the PACIFIC trial: Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.08.060_bib0004","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1097\/JTO.0b013e3182429682","article-title":"Defining local-regional control and its importance in locally advanced non-small cell lung carcinoma","volume":"7","author":"Machtay","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ijrobp.2025.08.060_bib0005","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.ijrobp.2019.08.034","article-title":"Patterns of disease progression with durvalumab in stage III non-small cell lung cancer (PACIFIC)","volume":"105","author":"Raben","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.08.060_bib0006","first-page":"953","article-title":"Pattern of failure following chemoradiation for locally advanced non-small cell lung cancer: Potential role for stereotactic body radiotherapy","volume":"30","author":"Nguyen","year":"2010","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ijrobp.2025.08.060_bib0007","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S1470-2045(14)71207-0","volume":"16","author":"Bradley","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2025.08.060_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109688","volume":"185","author":"Arcidiacono","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2025.08.060_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109492","article-title":"18F-FDG-PET guided vs whole tumour radiotherapy dose escalation in patients with locally advanced non-small cell lung cancer (PET-Boost): Results from a randomised clinical trial","volume":"181","author":"Cooke","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2025.08.060_bib0010","doi-asserted-by":"crossref","first-page":"6272","DOI":"10.21037\/jtd-21-573","article-title":"Sequential or concomitant chemotherapy with hypofractionated radiotherapy for locally advanced non-small cell lung cancer: A meta-analysis of randomized trials","volume":"13","author":"Viani","year":"2021","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.ijrobp.2025.08.060_bib0011","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.cllc.2014.08.002","article-title":"Radical-intent hypofractionated radiotherapy for locally advanced non-small-cell lung cancer: A systematic review of the literature","volume":"16","author":"Kaster","year":"2015","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.ijrobp.2025.08.060_bib0012","doi-asserted-by":"crossref","first-page":"32","DOI":"10.5603\/RPOR.a2021.0130","article-title":"Stereotactic radiotherapy for liver oligometastases","volume":"27","author":"Menichelli","year":"2022","journal-title":"Rep Pract Oncol Radiother"},{"key":"10.1016\/j.ijrobp.2025.08.060_bib0013","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20200645","article-title":"Stereotactic body radiotherapy for adrenal oligometastasis in lung cancer patients","volume":"93","author":"Arcidiacono","year":"2020","journal-title":"Br J Radiol"},{"key":"10.1016\/j.ijrobp.2025.08.060_bib0014","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1200\/JCO.18.00622","article-title":"Safety and efficacy of a five-fraction stereotactic body radiotherapy schedule for centrally located non\u2013small-cell lung cancer: NRG oncology\/RTOG 0813 trial","volume":"37","author":"Bezjak","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.08.060_bib0015","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S1470-2045(18)30896-9","article-title":"Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): A phase 3, open-label, randomised controlled trial","volume":"20","author":"Ball","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2025.08.060_bib0016","doi-asserted-by":"crossref","first-page":"529","DOI":"10.21037\/tlcr-2020-nsclc-04","article-title":"Systematic review of stereotactic body radiotherapy in stage III non-small cell lung cancer","volume":"10","author":"Alcibar","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.ijrobp.2025.08.060_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110439","article-title":"Stereotactic ablative radiotherapy for locally advanced non-small cell lung cancer: A systematic review and meta-analysis","volume":"201","author":"Viani","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2025.08.060_bib0018","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.ijrobp.2022.10.025","article-title":"STereotactic Ablative RadioTherapy in NEWly diagnosed and recurrent locally advanced non-small cell lung cancer patients unfit for ConcurrEnt RAdio-chemotherapy: Early analysis of the START-NEW-ERA non-randomised phase II trial","volume":"115","author":"Arcidiacono","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.08.060_bib0019","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1007\/s00066-016-1057-x","article-title":"Simultaneous integrated protection: A new concept for high-precision radiation therapy","volume":"192","author":"Brunner","year":"2016","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.ijrobp.2025.08.060_bib0020","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ijrobp.2015.05.004","article-title":"Precision hypofractionated radiation therapy in poor performing patients with non-small cell lung cancer: Phase 1 dose escalation trial","volume":"93","author":"Westover","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.08.060_bib0021","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.clon.2017.09.007","article-title":"UK consensus on normal tissue dose constraints for stereotactic radiotherapy","volume":"30","author":"Hanna","year":"2018","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"suppl 1","key":"10.1016\/j.ijrobp.2025.08.060_bib0022","doi-asserted-by":"crossref","first-page":"122S","DOI":"10.2967\/jnumed.108.057307","article-title":"From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors","volume":"50","author":"Wahl","year":"2009","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ijrobp.2025.08.060_bib0023","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.jtho.2021.03.019","article-title":"The HILUS-trial-a prospective Nordic multicenter phase 2 study of ultracentral lung tumors treated with stereotactic body radiotherapy","volume":"16","author":"Lindberg","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ijrobp.2025.08.060_bib0024","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.ijrobp.2023.06.246","article-title":"Expanded HILUS trial: A pooled analysis of risk factors for toxicity from stereotactic body radiation therapy of central and ultracentral lung tumors","volume":"117","author":"Lindberg","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.08.060_bib0025","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.ijrobp.2024.03.050","article-title":"Stereotactic radiation for ultra-central non-small cell lung cancer: A safety and efficacy trial (SUNSET)","volume":"120","author":"Giuliani","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.08.060_bib0026","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.jtho.2022.07.1148","article-title":"Durvalumab after sequential chemoradiotherapy in stage III, unresectable NSCLC: The phase 2 PACIFIC-6 trial","volume":"17","author":"Garassino","year":"2022","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ijrobp.2025.08.060_bib0027","doi-asserted-by":"crossref","first-page":"S1301","DOI":"10.1016\/j.annonc.2023.10.057","article-title":"LBA61 Durvalumab (durva) after sequential chemoradiotherapy (CRT) in patients (pts) with unresectable stage III NSCLC: Final analysis from PACIFIC-6","volume":"34","author":"Garassino","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2025.08.060_bib0028","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.ijrobp.2020.03.038","article-title":"Survival and toxicity of hypofractionated intensity modulated radiation therapy in 4 Gy fractions for unresectable stage III non-small cell lung cancer","volume":"107","author":"Kong","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.08.060_bib0029","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.ijrobp.2024.03.030","volume":"120","author":"Zhang","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.08.060_bib0030","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1001\/jamaoncol.2023.6033","article-title":"Accelerated hypofractionated chemoradiation followed by stereotactic ablative radiotherapy boost for locally advanced, unresectable non-small cell lung cancer: A nonrandomized controlled trial","volume":"10","author":"Wu","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2025.08.060_bib0031","article-title":"Dosimetric analysis of proximal bronchial tree subsegments to assess the risk of severe toxicity after stereotactic body radiation therapy of ultra-central lung tumors","volume":"45","author":"Ahmadsei","year":"2023","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2025.08.060_bib0032","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1093\/jrr\/rrac057","article-title":"Recurrence patterns and progression-free survival after chemoradiotherapy with or without consolidation durvalumab for stage III non-small cell lung cancer","volume":"64","author":"Kishi","year":"2023","journal-title":"J Radiat Res"},{"key":"10.1016\/j.ijrobp.2025.08.060_bib0033","first-page":"59","article-title":"Hypofractionated stereotactic body radiation therapy for elderly patients with stage IIB-IV nonsmall cell lung cancer who are ineligible for or refuse other treatment modalities","volume":"5","author":"Karam","year":"2014","journal-title":"Lung Cancer (Auckl)"},{"key":"10.1016\/j.ijrobp.2025.08.060_bib0034","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1111\/1759-7714.13105","article-title":"Outcomes and toxicity of stereotactic body radiation therapy for advanced stage ultra-central non-small cell lung cancer","volume":"10","author":"Cong","year":"2019","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.ijrobp.2025.08.060_bib0035","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s13014-019-1317-x","article-title":"Accelerated hypofractionated radiotherapy plus chemotherapy for inoperable locally advanced non-small-cell lung cancer: Final results of a prospective phase-II trial with a long-term follow-up","volume":"14","author":"Parisi","year":"2019","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2025.08.060_bib0036","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/COC.0000000000000892","article-title":"Stereotactic body radiotherapy and systemic dose chemotherapy for locally advanced lung cancer: Single arm phase 2 study","volume":"45","author":"Kubicek","year":"2022","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.08.060_bib0037","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s11604-021-01091-y","article-title":"Differences in patterns of recurrence of squamous cell carcinoma and adenocarcinoma after radiotherapy for stage III non-small cell lung cancer","volume":"39","author":"Katagiri","year":"2021","journal-title":"Jpn J Radiol"},{"key":"10.1016\/j.ijrobp.2025.08.060_bib0038","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.lungcan.2019.07.014","article-title":"Establishing a histology-specific biologically effective dose threshold for lung stereotactic ablative radiotherapy (SABR): Is \u2265100 Gy10 enough?","volume":"135","author":"Abel","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ijrobp.2025.08.060_bib0039","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1016\/j.jtho.2018.07.095","article-title":"Are we ready for histology-driven stereotactic ablative radiotherapy?","volume":"13","author":"D\u2019Angelillo","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ijrobp.2025.08.060_bib0040","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0169-5002(02)00038-7","article-title":"Older people with non small cell lung cancer in clinical stage IIIA and co-morbid conditions. Is curative irradiation feasible? Final results of a prospective study","volume":"37","author":"Pergolizzi","year":"2002","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ijrobp.2025.08.060_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102573","article-title":"Stereotactic body radiation therapy in unresectable stage III non-small cell lung cancer: A systematic review","volume":"118","author":"Allignet","year":"2023","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ijrobp.2025.08.060_bib0042","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.ijrobp.2024.06.036","article-title":"Enhancing outcomes in locally advanced non-small cell lung cancer through stereotactic dose escalation","volume":"120","author":"Simone","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.08.060_bib0043","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.ijrobp.2023.12.018","article-title":"Stereotactic body radiation therapy for stage IIA to IIIA inoperable non-small cell lung cancer: A phase 1 dose-escalation trial","volume":"119","author":"Rimner","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.08.060_bib0044","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1093\/neuonc\/noab129","article-title":"Immunotherapy in association with stereotactic radiotherapy for non-small cell lung cancer brain metastases: Results from a multicentric retrospective study on behalf of AIRO","volume":"23","author":"Scoccianti","year":"2021","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ijrobp.2025.08.060_bib0045","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1001\/jamaoncol.2023.5856","article-title":"Stereotactic body radiotherapy in locally advanced non\u2013small cell lung cancer-Is this the future?","volume":"10","author":"Lester-Coll","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2025.08.060_bib0046","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S1470-2045(24)00573-4","article-title":"Primary lung tumour stereotactic body radiotherapy followed by concurrent mediastinal chemoradiotherapy and adjuvant immunotherapy for locally advanced non-small-cell lung cancer: A multicentre, single-arm, phase 2 trial","volume":"26","author":"Heinzerling","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2025.08.060_bib0047","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1001\/jamaoncol.2019.1448","article-title":"Radiotherapy and immunotherapy-shining further together","volume":"5","author":"Walker","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2025.08.060_bib0048","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jtho.2019.12.106","article-title":"Combination of immunotherapy and radiotherapy-the next magic step in the management of lung cancer?","volume":"15","author":"Hendriks","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ijrobp.2025.08.060_bib0049","doi-asserted-by":"crossref","first-page":"S1302","DOI":"10.1016\/j.annonc.2023.10.058","article-title":"LBA62 durvalumab after radiotherapy (RT) in patients with unresectable stage III NSCLC ineligible for chemotherapy (CT): Primary results from the DUART study","volume":"34","author":"Filippi","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2025.08.060_bib0050","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1001\/jamaoncol.2023.3309","article-title":"Durvalumab plus concurrent radiotherapy for treatment of locally advanced non-small cell lung cancer: The DOLPHIN phase 2 nonrandomized controlled trial","volume":"9","author":"Tachihara","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2025.08.060_bib0051","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1200\/JCO.23.00627","article-title":"Selective personalized radioImmunotherapy for locally advanced non-small-cell lung cancer trial (SPRINT)","volume":"42","author":"Ohri","year":"2024","journal-title":"J Clin Oncol"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301625062091?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301625062091?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T13:05:21Z","timestamp":1773752721000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301625062091"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":51,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0360301625062091"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2025.08.060","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Five-Year Survival and Safety of SABR in Patients with Unresectable Locally Advanced Non-Small Cell Lung Cancer unfit for Concurrent Radio-chemotherapy: Focus on Patterns of Local Recurrence from the START-NEW-ERA Non-randomized Phase 2 Trial","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2025.08.060","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}